Ready to Talk
Colorado?

Contact Our Economic Development and Relocation Experts.

"*" indicates required fields

The information submitted through this form will be used by Colorado BioScience Association (CBSA) and Metro Denver Economic Corporation (MDEDC) for the purpose of evaluating and facilitating economic development opportunities. It will be handled with the utmost confidentiality and will not be disclosed to third parties without explicit consent.

Colorado’s Life Sciences Community Raises $1.2 Billion in First Two Quarters of 2024 

Colorado’s Life Sciences Community Raises $1.2 Billion in First Two Quarters of 2024

Colorado’s Life Sciences Community Raises $1.2 Billion in First Two Quarters of 2024 

 Colorado’s life sciences community raised $1.2 billion in the first two quarters of 2024. Public and private capital, as well as federal and state grants contributed to the fundraising totals January 1, 2024-June 30, 2024.  

The continued strong fundraising comes after CNBC highlighted the fundraising momentum of Colorado’s life sciences community during its “Cities of Success” special report. The ecosystem’s fundraising now stands at $11 billion raised in the last seven years and six months.  

“Colorado is the Hub for Health Impact, with life sciences financings surging past the billion-dollar mark in the first two quarters of 2024,” said Elyse Blazevich, President & CEO of Colorado BioScience Association. “Health innovations from Colorado save and change lives around the world and investors want to seize opportunities here.” 

Fundraising Totals
In the first two quarters of 2024, Colorado companies raised $794.6 million in public capital through M&A, post-IPO debt, and post-IPO equity. Companies and the state’s academic and research institutions also received $257.9 million in state, federal and foundation grants. Colorado life sciences companies also raised $155.3 million in private capital. 

Venture Capital Totals  
Pre-Seed and Seed: $8.9M
Series A and B: $111.4M 
Series C, D, and Later: $35M 

Colorado Life Sciences Financing History 
2024 Q1 and Q2: $1.2 billion
2023: $1.47 billion
2022: $1.6 billion
2021: $2.4 billion
2020: $1.2 billion, $2.6 billion including Invitae acquisition of ArcherDX 
2019: $850 million, $12.1 billion including Pfizer acquisition of Array Biopharma
2018: $1 billion
2017: $1.2 billion

Colorado BioScience Association compiles and analyzes annual life sciences financings using publicly available sources, including company news releases, media reports, SEC filings, federal and state databases, and Crunchbase. 

Click here for the full article.